Aducanumab for Alzheimer's Disease

"This specific medical trial is searching for individuals that are 50 years old or above, and younger than 90 years old."

"Aducanumab was given a safety score of 3 by our team at Power. This is because Aducanumab is currently in Phase 3 trials, which implies that there is some evidence suggesting the medication's efficacy as well as multiple rounds of data affirming its safety."

"Aducanumab was first researched at Wake Forest Baptist Health in 2020. So far, 5 studies have been completed while 2 are ongoing. These active trials are based in New york City."

"Research into Aducanumab began in 2020 with a study sponsored by Biogen. After the initial Phase 3 clinical trial, which had 1696 participants, the drug received approval. As of now, there are 2 ongoing studies involving Aducanumab being conducted in 202 cities across 20 countries."

"This trial is enrolling 1696 patients with Alzheimer's disease who are between the ages of 50 and 90. The following criteria must also be met: Participant was participating in an aducanumab clinical study at the time of the announcement of early termination (feeder studies)., Has one care partner who, in the Investigator's opinion, has adequate contact with the participant as to be able to provide accurate information about the participant's cognitive and functional abilities., Participant must have completed the Core study period (Week 102) and adequately tolerated 10 mg/kg of aducanumab during the Core study period in the opinion of"